The mental health crisis that gained attention during the COVID-19 pandemic hasn’t subsided, and its effects are being felt in the workplace across a multitude of industries.
As automation takes over administrative tasks, claims specialists are discovering new opportunities to focus on what technology cannot replicate: empathy, judgment, and meaningful communication with injured workers.
As AI reshapes the competitive landscape, technology companies are pursuing bigger acquisitions despite declining deal volume, with blockbuster transactions exceeding $30 billion becoming the new normal.
Despite declining transaction volume in 2024, life sciences companies are pursuing bigger acquisitions to secure drug portfolios, integrate AI capabilities, and navigate the looming patent cliff.